Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: A two-stage design with a preliminary performance study and a mass screening in southern China

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages 406-416

  Liu, Yue ^a   Huang, Qihong ^b   Liu, Wanli ^a   Liu, Qing ^a   Jia, Weihua ^a   Chang, Ellen ^c,d   Chen, Feng ^a   Liu, Zhiwei ^a   Guo, Xiang ^a   Mo, Haoyuan ^a   Chen, Jinou ^e   Rao, Dongping ^e   Ye, Weimin ^f   Cao, Sumei ^a   Hong, Minghuang ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Sihui Cancer Institute   (China)

^c CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SUN YAT SEN UNIVERSITY   (China)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Epstein Barr virus antibodies; mass screening; nasopharyngeal carcinoma; tumor markers

Indexed keywords

BRLF1 TRANSCRIPTION ACTIVATOR PROTEIN; EARLY ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; IMMEDIATE EARLY PROTEIN BZLF1; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; TRANSACTIVATOR PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; VIRUS CAPSID ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; CANCER SCREENING; CASE CONTROL STUDY; CHINA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NASOPHARYNX CARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; TEST RETEST RELIABILITY;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID; CAPSID PROTEINS; CHINA; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; MALE; MASS SCREENING; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS;

EID: 84861624791     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26380     Document Type: Article

References (45)

1. Chang ET, Adami HO,. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15: 1765-77.
2. Chen C, Liang K, Chang Y, Wang Y, Hsieh T, Hsu M, Chen J, Liu M,. Multiple risk factors of nasopharyngeal carcinoma: Epstein-Barr virus, malarial infection, cigarette smoking and familial tendency. Anticancer Res 1990; 10: 547-53.
3. Ma J, Cao S,. The epidemiology of nasopharyngeal carcinoma. In:, Lu JJ, Cooper JS, Lee AWM, eds. Nasopharyngeal Cancered. Berlin Heidelberg: Springer, 2010. 1-8.
4. Jia W-H, Huang Q-H, Liao J, Ye W, Shugart YY, Liu Q, Chen L-Z, Li Y-H, Lin X, Wen F-L, Adami H-O, Zeng Y, et al. Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer 2006; 6: 178-85.
5. Henle G, Henle W,. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976; 17: 1-7.
6. Old L, Boyse E, Oettgen H, De Harven E, Geering G, Williamson B, Clifford P,. Precipitating antibody in human serum to an antigen present in cultured Burkitt's lymphoma cells. Proc Natl Acad Sci USA 1966; 56: 1699-704.
7. Yi Z, Yuxi L, Chunren L, Sanwen C, Jihneng W, Jisong Z, Huijong Z,. Application of an immunoenzymatic method and an immunoautoradiographic method for a mass survey of nasopharyngeal carcinoma. Intervirology 1980; 13: 162-8.
8. Tang B, Liu Q, Cui Y, Hong M, Zhu X, Yue H,. Protocols of screening, early detection and diagnosis for nasopharyngeal carcinoma. In:, Dong Z, Qiao Y, eds. Protocols of screening, early detection and diagnosis for cancer in P.R.Chinaed. Beijing: People's Medical Publishing House of P.R. China, 2009. 187-8.
9. Huang T, Wang H, Li J,. Establishment of high risk population and precancerous lesions of nasopharyngeal carcinoma. Chin J Cancer 1997; 16: 81-4.
10. Gan Y, Fones-Tan A, Chan S, Gan L,. Epstein-Barr viral antigens used in the diagnosis of nasopharyngeal carcinoma. J Biomed Sci 1996; 3: 159-69.
11. Tang J, Rohwader E, Chu I, Tsang R, Steinhagen K, Yeung A, To K, Chan P,. Evaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma. J Clin Virol 2007; 40: 284-8.
12. Chen M, Liu M, Hsu S, Fong C, Chen C, Chen I, Hsu M, Yang C, Chen J,. Use of bacterially expressed EBNA-1 protein cloned from a nasopharyngeal carcinoma (NPC) biopsy as a screening test for NPC patients. J Med Virol 2001; 64: 51-7.
13. Joab I, Nicolas J, Schwaab G,. Detection of anti-Epstein-Barr-virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. Int J Cancer 1991; 48: 647-9.
14. Yip T, Ngan R, Lau W, Poon Y, Joab I, Cochet C, Cheng K,. A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer 1994; 74: 2414-24.
15. Feng P, Chan S, Soo M, Liu D, Guan M, Ren E, Hu H,. Antibody response to Epstein-Barr virus Rta protein in patients with nasopharyngeal carcinoma. Cancer 2001; 92: 1872-80.
16. Humme S, Reisbach G, Feederle R, Delecluse H, Bousset K, Hammerschmidt W, Schepers A,. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc Natl Acad Sci USA 2003; 100: 10989-94.
17. Chan KH, Gu YL, Ng F, Ng PS, Seto WH, Sham JS, Chua D, Wei W, Chen YL, Luk W, Zong YS, Ng MH,. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer 2003; 105: 706-9.
18. Cheng W-m, Chan KH, Chen H-l, Luo R-x, Ng SP, Luk W, Zheng B-j, Ji M-f, Liang J-s, Sham JST, Wang D-K, Zong Y-s, et al. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Int J Cancer 2002; 97: 489-92.
19. Dardari R, Hinderer W, Lang D, Benider A, El Gueddari B, Joab I, Benslimane A, Khyatti M,. Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigens p54 and p138. J Clin Microbiol 2001; 39: 3164-70.
20. Wong M, Lye M, Cheng H, Sam C,. Epstein-Barr virus serology in the diagnosis of nasopharyngeal carcinoma. Asian Pac J Allergy Immunol 2005; 23: 65-7.
21. Hsu M, Hsu W, Sheen T, Kao C,. Specific IgA antibodies to recombinant early and nuclear antigens of Epstein-Barr virus in nasopharyngeal carcinoma1. Clin Otolaryngol Allied Sci 2001; 26: 334-8.
22. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y,. Phases of biomarker development for early detection of cancer. J Natl Cancer I 2001; 93: 1054-61.
23. Baker SG, Kramer BS, Prorok PC,. Development tracks for cancer prevention markers. Dis markers 2004; 20: 97-102.
24. Baker SG, Kramer BS, McIntosh M, Patterson BH, Shyr Y, Skates S,. Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials 2006; 3: 43-56.
25. Hong MH, Mai HQ, Min HQ, Ma J, Zhang EP, Cui NJ,. A comparison of the Chinese 1992 and fifth-edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma. Cancer 2000; 89: 242-7.
26. Ooka T, de Turenne-Tessier M, Stolzenberg MC,. Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases. Springer Semin Immunopathol 1991; 13: 233-47.
27. Gu A-D, Lu L-X, Xie Y-B, Chen L-Z, Feng Q-S, Kang T, Jia W-H, Zeng Y-X,. Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology. J Transl Med 2009; 7: 73-8.
28. Tsuchiya S,. Diagnosis of Epstein-Barr virus-associated diseases. Crit Rev Oncol Hematol 2002; 44: 227-38.
29. Shanmugaratnam K, Sobin L,. The World Health Organization histological classification of tumours of the upper respiratory tract and ear. Cancer 1993; 71: 2689-97.
30. Engvall E, Perlmann P,. Enzyme-linked immunosorbent assay, ELISA. The J Immunol 1972; 109: 129-35.
31. Halprin J, Scott AL, Jacobson L, Levine PH, Ho J, Niederman JC, Hayward SD, Milman G,. Enzyme-linked immunosorbent assay of antibodies to Epstein-Barr virus nuclear and early antigens in patients with infectious mononucleosis and nasopharyngeal carcinoma. Ann Intern Med 1986; 104: 331-7.
32. McGraw K, Wong S,. Forming inferences about some intraclass correlation coefficients. Psychol Methods 1996; 1: 30-46.
33. Simel D, Samsa G, Matchar D,. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol 1991; 44: 763-70.
34. Kosinski A, Barnhart H,. A global sensitivity analysis of performance of a medical diagnostic test when verification bias is present. Stat Med 2003; 22: 2711-21.
35. Rubin D,. Inference and missing data. Biometrika 1976; 63: 581-92.
36. Fleiss JL,. Reliability of measurement. The design and analysis of clinical experiments, 1st edn. New York: Wiley-Interscience, 1986. 1-32.
37. Lou P, Hsu W, Chien Y, Chen C,. Screening and early diagnosis of nasopharyngeal carcinoma. Nasopharyngeal Cancer 2010: 53-64.
38. Karray H, Ayadi W, Fki L, Hammami A, Daoud J, Drira MM, Frikha M, Jlidi R, Middeldorp JM,. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. J Med Virol 2005; 75: 593-602.
39. Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, Kusumo H, Zeng YS, Schouten T, Mubarika S, Middeldorp JM,. Single-assay combination of Epstein-Barr virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV Immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. J Clin Microbiol 2006; 44: 1459-67.
40. Cao SM, Liu Z, Jia WH, Huang QH, Liu Q, Guo X, Huang TB, Ye W, Hong MH,. Fluctuations of Epstein-Barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PloS one 2011; 6: e19100.
41. Leung Sf,. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem 2004; 50: 339-45.
42. Mo H, Chen D, Hong M,. Study of local tumor involvement in nasopharyngeal carcinoma with fiberendoscope, CT scanning, and pathological evidence. Chin J Cancer 1998; 17: 293-5.
43. Zhou X, Castelluccio P,. Adjusting for non-ignorable verification bias in clinical studies for Alzheimer's disease. Stat Med 2004; 23: 221-30.
44. Gaffikin L, McGrath J, Arbyn M, Blumenthal P,. Avoiding verification bias in screening test evaluation in resource poor settings: a case study from Zimbabwe. Clin Trials 2008; 5: 496-503.
45. Day NE,. Estimating the sensitivity of a screening test. J Epidemiol Community Health 1985; 39: 364-6.